Analyst’s mean target price for Mylan N.V. (NASDAQ:MYL) is $58.31 while analysts mean recommendation is 2.10.
Advertisement
NIKE, Inc. (NYSE:NKE) announced that its Board of Directors has declared a quarterly cash dividend of $0.16 per share on the company’s outstanding Class A and Class B Common Stock payable on October 3, 2016, to shareholders of record at the close of business on September 6, 2016.
The Boeing Company (NYSE:BA) received $2 billion in performance bonuses from the Pentagon for a missile defense system that failed more than half the time in flight tests. Mylan NV are listed in the Health Care sector within NASDAQ. The Pentagon paid the company more than $21 billion to manage the system from 2002 until early a year ago, the Los Angeles Times reported, and the system has cost more than $40 billion since it became operational in 2004. Leerink Swann maintained the stock on August 15 with “Outperform” rating. Mylan has a 52 week low of $37.59 and a 52 week high of $55.51. During the same period in the previous year, the firm posted $0.91 earnings per share.
This story is the sole property of American Banking News and it was originally published by American Banking News. Wellington Management Group LLP boosted its position in shares of Mylan by 1.2% in the first quarter. The stock concluded the recent trade at $39.97 with downbeat trend move of -4.65%. (NYSE:BKD) [Trend Analysis] shows fluctuation in active trade, on Monday shares shows upbeat performance surged 3.59% to $17.60. Norges Bank bought a new stake in shares of Mylan during the fourth quarter valued at $172,977,000. The ratio is negative, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. The stocks closing price on Thursday was $41.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
However, some analysts claimed that Mylan’s way of showering incentives could have been led by their EpiPen’s price increase, citing high demands mainly from school-age children and others who are dependent on reverse severe allergic reactions. BTIG Research restated a “buy” rating and issued a $60.00 price target on shares of Mylan in a research note on Tuesday, August 30th.
The chart below illustrates MYL respond in their recent aggressive incentives for executives, in which the stock price opened at $48.99 on August 19 and tried to break out at support 46.35 on the downside. In the past twelve weeks, the net percent change held by company insiders has changed by -10.79%.
Mylan N.V. formerly Mylan Inc.is a global pharmaceutical company which develops licenses manufactures markets and distributes generic branded generic and specialty pharmaceuticals.
Mylan CEO Heather Bresch commented, “Through noteworthyinvestment in research and development and by challenging these invalid patents, we are working to bring a more affordable generic alternative of Copaxone® to market”.
Advertisement
Receive News & Ratings for Mylan Inc. Mylan Inc. has been the topic of 11 analyst reports since September 11, 2015 according to StockzIntelligence Inc.
